This video examines results of a phase II trial that studied the combination of neratinib plus capecitabine for the treatment of recurrent brain metastases in HER2-positive breast cancer patients.
Rachel A. Freedman, MD, MPH
Advertisement
Articles by Rachel A. Freedman, MD, MPH
Advertisement
Latest Updated Articles
Neratinib Shrank Brain Mets in Half of HER2+ Breast Cancer PatientsPublished: June 6th 2017 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Atezolizumab Combo Elicits No Significant Benefit in Ovarian Cancer
2
Glofitamab/Polatuzumab Vedotin Exhibits Response Durability in R/R LBCL
3
Muscle RNome Analysis Reveals 2 Molecular Subtypes Associated With Cancer Cachexia
4
Short-Course Radiation May Be Feasible in Older Rectal Cancer Population
5
